“Randomised trials of CABG v PCI are no longer possible and cannot represent real life practice.” Dr Rod Stables The Cardiothoracic Centre Liverpool UK.

Slides:



Advertisements
Similar presentations
Complex Lesion Subsets: Indications for DES Andreas Baumbach, MD, FRCP, FESC Bristol Heart Institute.
Advertisements

Is this the “spioenkop” for CABG?
In Diabetics with Ischemic Heart Disease CABG revascularization is always superior? Dr. Paolo Ferrazzi.
CABG VS Multi Vessel PCI Hasanat Sharif MD FRCS Chief of Cardiorthoracic Surgery Aga Khan University Hospital.
BBC ONE David Hildick-Smith Sussex Cardiac Centre Brighton, UK on behalf of the BBC ONE Investigators.
Professor Abdus Samad MD FACC Karachi Institute of Heart Diseases Karachi, Pakistan May 1, 2010.
Coronary Revascularisation in Patients With Diabetes Mellitus Dr Rod Stables The Cardiothoracic Centre Liverpool UK.
ARTS I & II Keith D Dawkins Southampton University Hospital.
Clifford W. Barlow (FRCS, DPhil) Southampton General Hospital Southampton, UK.
PCI VS CABG JOURNAL REVIEW
ST-Elevation Myocardial Infarction & Cardiogenic Shock - What Should We Do? Advanced Angioplasty 2008 Dan Blackman Leeds General Infirmary.
C.H.T Dr.Salarifar 1 Tehran Heart Center Tehran University of Medical Sciences PCI VS CABG M. SALARIFAR, MD.
1 1 The Use of Percutaneous Coronary Intervention in Patients with Class I Indications for Coronary Artery Bypass Graft Surgery: Data from the National.
What Do We Mean By Quality In PCI Institutional Requirements Dr Bernard Prendergast John Radcliffe Hospital, Oxford.
BIOE 301 Lecture Seventeen. Guest Speaker Jay Brollier World Camp Malawi.
Coronary Artery Disease in Diabetic Patients, Different from Non-diabetics?
Stent or Surgery: What is Best for a Woman ? Dr R H Stables Cardiothoracic Centre Liverpool UK.
CPORT- E Trial Randomized trial comparing outcomes of non-primary PCI at hospitals with and without on-site cardiac surgery.
Disclosures The presenter has no financial involvement with the product or competing products being discussed. The presenter received travel and lodging.
Advanced Angioplasty 2006 Trial Update 2 Other Trials Alun Harcombe from 1 April: Nottingham University Hospitals NHS Trust NO CONFLICT OF INTEREST TO.
Professor Martin T Rothman Director Cardiac Research & Development Barts & The London NHS Trust London, England Professor Martin T Rothman Director Cardiac.
Does Openness Improve Outcome ? The North-West Quality Improvement Program Dr R H Stables Cardiothoracic Centre Liverpool.
BIOE 301 Lecture Seventeen. Progression of Heart Disease High Blood Pressure High Cholesterol Levels Atherosclerosis Ischemia Heart Attack Heart Failure.
Top Trial Cheats Dr Rod Stables The Cardiothoracic Centre Liverpool UK No Conflicts of Interest to Declare.
Unresolved issues with Drug-eluting Stents Stent Thrombosis Advanced Angioplasty 2007 Dan Blackman Yorkshire Heart Centre.
EXAMINATION Objective Assess the safety and performance of a new-generation DES vs. a BMS in the setting of primary PCI for treatment of patients with.
Heart Attack Centres: Every Network Should Have (at least) One Dr Rod Stables The Liverpool Heart and Chest Hospital.
U.K. ROLL-OUT OF DRUG-ELUTING STENTS JIM McLENACHAN, YORKSHIRE HEART CENTRE, LEEDS. ADVANCED ANGIOPLASTY 17 th JANUARY, 2003.
AICT 2010-Athens Interventional Cardiovascular Therapeutics XI 8-9 OCTOBER 2010 Divani Caravel Hotel, Αthens EARLY CLINICAL OUTCOMES AFTER PROMUS ELEMENT.
BME 301 Lecture Nineteen. Progression of Heart Disease High Blood Pressure High Cholesterol Levels Atherosclerosis Ischemia Heart Attack Heart Failure.
Trial Design Issues Associated with Evaluation of Distal Protection Devices in Diseased Saphenous Vein Grafts Bram D. Zuckerman, MD, FACC Medical Officer,
CABG versus PCI for Lmain/3 V-D: SYNTAX trial 3 year
David Hildick-Smith Sussex Cardiac Centre. Background to ARTS Previous POBA studies Meta-analysis 3300 patients 1660 CABG, 1710 PTCA Deaths 79 PCI vs.
Coronary Revascularisation: the DoH View Dr Roger Boyle National Director for Heart Disease.
PCI v CABG Dr Rod Stables The Cardiothoracic Centre Liverpool UK.
BME 301 Lecture Nineteen. Progression of Heart Disease High Blood Pressure High Cholesterol Levels Atherosclerosis Ischemia Heart Attack Heart Failure.
Multivessel Coronary Artery Disease
Methodological Issues in Implantable Medical Device(IMDs) Studies Abdallah ABOUIHIA Senior Statistician, Medtronic.
Samuel Thomas Rayburn, III MD Cardiovascular Surgeon Jack Stephens Heart Institute April 25, 2015.
Date of download: 7/10/2016 Copyright © The American College of Cardiology. All rights reserved. From: Risk of Stroke With Coronary Artery Bypass Graft.
“Randomised trials of CABG v PCI are no longer possible & cannot represent real life clinical practice” “Randomised trials of CABG v PCI are no longer.
Survival Benefits in Higher Risk Patients Coronary Revascularization has Revolutionized the Therapy of Ischemic Heart Disease Acute coronary syndromes.
Revascularization Strategy: Syntax Score and Beyond
Consistency in diagnostic and treatment procedures Specifically angiography and angioplasty Dr Alison Round 14 October 2015.
Prof. Dr. med. Sigmund Silber Cardiology Practice and Hospital
Final Five-Year Follow-up of the SYNTAX Trial: Optimal Revascularization Strategy in Patients With Three-Vessel Disease and/or Left Main Disease Patrick.
Figure 1 A flow chart describing the systematic process followed for article selection.  From: A systematic review of cost-effectiveness of percutaneous.
Damian Gimpel Waikato Cardiothoracic Unit Journal Club
Within Trial Decisions: Unblinding and Termination
On-Site Surgical Back-up is ‘Critically’ Important for PCI!
The Syntax Trial: PCI versus CABG
On behalf of J. Belardi, M. Leon, L. Mauri,
Jeff Macemon Waikato Cardiothoracic Unit
Percutaneous coronary invervention versus coronary artery bypass grafting: A meta- analysis  Yolba Smit, MD, MSc, Joan Vlayen, MD, Hetty Koppenaal, MD,
Table. Clinical Efficacy and Safety
Ten Key Trials in Cardiovascular Surgery
Preventive Angioplasty in Myocardial Infarction Trial
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
Proposed new acute variceal bleeding (AVB) management algorithm.
(p = 0.32 for noninferiority)
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
Martin B. Leon, David R. Holmes, Dean J. Kereiakes, Jeffrey J
Maintenance of Long-Term Clinical Benefit with
DEScover: One-Year Clinical Results
Ahmed A. Khattab, MD For the German Cypher Registry Investigators
To bypass or stent? The changing rules of an advancing game
Atlantic Cardiovascular Patient Outcomes Research Team
The American College of Cardiology Presented by Dr. A. Abazid
NOBLE Trial design: Patients with unprotected left main disease were randomized to either PCI with a drug-eluting stent (DES) (88% biolimus) or CABG. They.
Cardiovascular Epidemiology and Epidemiological Modelling
Presentation transcript:

“Randomised trials of CABG v PCI are no longer possible and cannot represent real life practice.” Dr Rod Stables The Cardiothoracic Centre Liverpool UK No Conflicts of Interest to Declare

PCI v CABG - Current Trials They can be done - they are being done ! CARDIA SYNTAX FREEDOM COMBAT Le MANS They must be done

HEART 2005 PCI Supplement

Key Article by Respected Opinion Leader “It is now especially important to compare, by randomised study, the outcome of LM stenting with CABG …..”

Err …… That’s it Thank you

If You Support This Motion …….. For multi-vessel revascularisation CABG surgery is the evidence based choice Diabetics Left main stem disease 3 vessel disease (Occlusions bifurcations diffuse disease) Many PCI operators do not accept this reality

Adoption of a New ‘Surgical’ Technology Wilson BMJ 2006;332: Time Adoption of Technology % RCT evidence proves safety and efficacy

Captain’s Log – Stardate: Early Stent Era c1994 Clinical outcomes – the reality Procedural mortality - 1.5% Immediate emergency CABG - 4% Sub-acute thrombosis (=MI) - 3% Bleeding or puncture site comps - 5% Repeat revascularisation - 16 – 45% Clinical disaster area: PCI docs think its great ! Exponential growth in procedure numbers

Sir Winston Churchill on Angioplasty ‘Success is the ability to go from one failure to another with no loss of enthusiasm’ Witness: observation of live cases at the annual LMS meeting !!

The Enthusiasm Hypothesis of Healthcare Variation Faith or belief in a procedure - Extends beyond or ignores evidence base Usually involves self-referral Control of the patient base Drives case volume expansion in PCI Stimulus for continuing advancement Improving clinical outcomes Progress charted with sequential RCTs

Clinical Outcomes : Is PCI Playing Catch-up Control of the patients and self-referral Rare, substantial and convenient power Carries great responsibility Must continue to measure against the Tx norm In the (internal) development of PCI Against alternative treatment strategies

RCTs - The Evidence Gold Standard Procedure based RCTs Limitations Challenges Obstacles

PCI v CABG : RCT Problems Scale and funding Patient consent Operator skills Keeping pace with new developments Patient selection and ability to generalise results

PCI v CABG : RCT Problems PCI doctors Initiate and control trials Design protocols and outcome measures Recruit patients Assess outcome measures Holding all the cards We MUST win (or even draw) ONCE

Lancet January

“Randomised trials of CABG v PCI are no longer possible and cannot represent real life practice.”